Clincosm LogoSign in Get a demo

Malignant Melanoma

Showing 26 - 50 of 202
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Melanoma Trial in Los Angeles, Houston, Uppsala (delolimogene mupadenorepvec, atezolizumab)

Recruiting
  • Malignant Melanoma
  • delolimogene mupadenorepvec
  • atezolizumab
  • Los Angeles, California
  • +2 more
Apr 4, 2022

GI Complications in Cancer Immunotherapy Patients

Recruiting
  • Malignant Melanoma
    • Boston, Massachusetts
      Massachusetts General Hospital
    Apr 4, 2022

    Malignant Melanoma Trial in San Diego, Memphis, Houston (Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b)

    Active, not recruiting
    Has Results
    • Malignant Melanoma
    • Peginterferon alfa-2b
    • +2 more
    • San Diego, California
    • +2 more
    Apr 1, 2022

    Malignant Melanoma, Metastatic Melanoma, Immunotherapy Trial (Pembrolizumab, Encorafenib, Binimetinib)

    Not yet recruiting
    • Malignant Melanoma
    • +4 more
    • (no location specified)
    Mar 31, 2022

    Malignant Melanoma, NSCLC, Renal Cell Cancer Trial in United Kingdom (ImmuniCell®)

    Terminated
    • Malignant Melanoma
    • +2 more
    • ImmuniCell®
    • Cardiff, United Kingdom
    • +6 more
    Mar 8, 2022

    Vitamin D Status in Anti-PD1 Treated Melanoma Patients

    Completed
    • Malignant Melanoma
    • Aarhus, Denmark
      AUH
    Feb 16, 2022

    Malignant Melanoma Trial in Germany, Italy (4SC-202 in combination with Pembrolizumab)

    Completed
    • Malignant Melanoma
    • 4SC-202 in combination with Pembrolizumab
    • Essen, Germany
    • +6 more
    Feb 3, 2022

    Solid Tumor, Breast Cancer, Small Cell and NSCLC Trial in Hackensack (RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior

    Recruiting
    • Solid Tumor
    • +15 more
    • RAPA-201 Rapamycin Resistant T Cells
    • Chemotherapy Prior to RAPA-201 Therapy
    • Hackensack, New Jersey
      Hackensack University Medical Center
    Dec 23, 2021

    Malignant Melanoma Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

    Active, not recruiting
    • Malignant Melanoma
    • Pembrolizumab
    • +2 more
    • Beijing, Beijing, China
    • +10 more
    Dec 22, 2021

    Malignant Melanoma Trial in Germany (Nivolumab + Placebo, Nivolumab + Ipilimumab, Double Placebo Control)

    Completed
    • Malignant Melanoma
    • Nivolumab + Placebo
    • +2 more
    • Berlin, Germany
    • +19 more
    Dec 10, 2021

    Pre Transplantation Melanoma

    Completed
    • Malignant Melanoma
    • patient with melanoma pre transplantation
    • Lyon, Rhone, France
      service de dermatologie - hopital Edouard Herriot
    Dec 9, 2021

    Malignant Melanoma Trial (tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy)

    Withdrawn
    • Malignant Melanoma
    • tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
    • (no location specified)
    Nov 12, 2021

    Malignant Melanoma Trial in Worldwide (Atezolizumab, Cobimetinib)

    Completed
    Has Results
    • Malignant Melanoma
    • Scottsdale, Arizona
    • +42 more
    Nov 17, 2021

    Malignant Melanoma Trial in Norway (Blood sampling for Pre-existing immunity, Ipilimumab)

    Active, not recruiting
    • Malignant Melanoma
    • Bergen, Norway
    • +7 more
    Oct 22, 2021

    Malignant Melanoma Trial in Worldwide (Dabrafenib, Trametinib)

    Completed
    • Malignant Melanoma
    • Rosario, Sante Fe, Argentina
    • +99 more
    Oct 14, 2021

    PET Imaging of the Immune System Using Analog Probes

    Completed
    • Malignant Melanoma
    • [18F] CFA
    • Los Angeles, California
      University of California, Los Angeles
    Oct 8, 2021

    Malignant Melanoma Trial in Herlev (Cyclophosphamide, Fludarabine Phosphate, Multiple Antigen Specific Endogenously derived T

    Recruiting
    • Malignant Melanoma
    • Herlev, Denmark
      National Center for Cancer Immune Therapy (CCIT-DK)
    Sep 14, 2021

    Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial in United States (ZN-c3)

    Recruiting
    • Solid Tumor
    • +9 more
    • Tucson, Arizona
    • +3 more
    Aug 12, 2021

    Malignant Melanoma Trial in United Kingdom (PLX3397)

    Completed
    • Malignant Melanoma
    • Manchester, Greater Manchester, United Kingdom
    • +7 more
    Aug 11, 2021

    Malignant Melanoma Trial in Brussels (MAGE-3.A1 peptide and CpG 7909)

    Terminated
    Has Results
    • Malignant Melanoma
    • MAGE-3.A1 peptide and CpG 7909
    • Brussels, Belgium
    • +1 more
    Aug 2, 2021

    Melanoma, Malignant Melanoma Trial in Stockholm (Immunostimulating Interstitial Laser Thermotherapy)

    Terminated
    • Melanoma
    • Malignant Melanoma
    • Immunostimulating Interstitial Laser Thermotherapy
    • Stockholm, Sweden
      Karolinska University Hospital Solna
    Jul 2, 2021

    Malignant Melanoma Trial (Tislelizumab)

    Not yet recruiting
    • Malignant Melanoma
    • (no location specified)
    Jun 15, 2021

    Malignant Melanoma Trial in Oslo (Ipilimumab, UV1 vaccine, GM-CSF)

    Active, not recruiting
    • Malignant Melanoma
    • Oslo, Norway
      Oslo University Hospital, Radiumhospitalet
    May 14, 2021

    Malignant Melanoma Trial in Hangzhou (toripalimab, Temozolomide Injection)

    Recruiting
    • Malignant Melanoma
    • Hangzhou, Zhejiang, China
      Department of Medical Onocology, First Affiliated Hospital of Zh
    May 10, 2021

    Malignant Melanoma Trial in Kansas City (Wide Local Excision)

    Completed
    • Malignant Melanoma
    • Wide Local Excision
    • Kansas City, Kansas
      University of Kansas Medical Center
    Apr 29, 2021